Welcome to Procognia
Procognia (Israel) Ltd. is a world leader in glycobiology, with an exclusive range of proprietary technologies and applications covering four key platforms: analytics, diagnostics, therapeutic antibodies and stem cells. A publicly traded company on the Tel Aviv Stock Exchange (TASE: PRCG), Procognia established itself as a dominant player in glycomics with the development of an innovative high throughput lectin array based glycoanalysis platform technology, the GlycoScopeTM.
Based on its expertise, the company is currently focusing on the development of breakthrough in-vitro and in-vivo cancer diagnostics, targeted cancer therapy technologies and stem cell applications.
Procognia's R& D team is working intensively to continue the development of leading technologies in glycobiology, and to strengthen the company's contribution to a new generation of biomedical applications.
News&Events
01/05/2012
read more
TEL-AVIV, Israel, Procognia (TASE: PRCG) is pleased to announce the release of its new upgraded glycoanalysis product, the Multi Pad GlycoScope
20/03/2012
read more
Procognia announced that the feasibility stage of the company's research in cooperation with the Weizmann Institute of Science has been successfully completed. This research aims to use Procognia's unique glycoprofiling technology as an optimal tool to identify and develop stem cells
04/03/2012
read more
Procognia signs binding letter of intent with Beijing Cy-Tech for the exclusive marketing and distribution of its GlycoScope product in the Greater China Region
3/08/2011
read more
Procognia Signs Research and Development Agreement with Caerus Discovery
